Table 2 Reasons for treatment changes according to each individual DMT
Alemtuzumab | Dimethylfumarate | Fingolimod | Glatiramer | Interferons | Natalizumab | Rituximab | Teriflunomide | |
|---|---|---|---|---|---|---|---|---|
Treatment switch ( N = 404) | ||||||||
Total | 3 | 7 | 79 | 22 | 219 | 47 | 4 | 23 |
Disease activity n (%) | 3 (100) | 3 (42.9) | 62 (77.2) | 9 (40.1) | 116 (52.9) | 11 (23.4) | 2 (50.0) | 14 (60.8) |
Safety n (%) | 0 (0.0) | 2 (28.6) | 11 (13.9) | 4 (18.2) | 69 (31.5) | 4 (8.5) | 1 (25.0) | 6 (26.1) |
Reproductive issues n (%) | 0 (0.0) | 0 (0.0) | 1 (1.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Administrative issues n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (9.5) | 6 (2.8) | 1 (2.1) | 0 (0.0) | 0 (0.0) |
JC virus n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 33 (70.2) | 0 (0.0) | 0 (0.0) |
Other n (%) | 0 (0.0) | 0 (0.0) | 3 (3.8) | 2 (9.5) | 7 (3.2) | 1 (2.1) | 1 (25.0) | 1 (4.3) |
Unknown n (%) | 0 (0.0) | 2 (28.6) | 3 (3.8) | 4 (18.2) | 33 (15.1) | 2 (4.3) | 0 (0.0) | 2 (8.7) |
Treatment suspension ( N = 186) | ||||||||
Total | 2 | 5 | 21 | 11 | 106 | 24 | 9 | 8 |
Disease activity n (%) | 0 (0.0) | 0 (0.0) | 1 (4.8) | 0 (0.0) | 15 (14.2) | 1 (4.2) | 2 (25.0) | 0 (0.0) |
Safety n (%) | 0 (0.0) | 2 (40.0) | 3 (14.3) | 2 (18.2) | 27 (25.5) | 0 (0.0) | 1 (12.5) | 1 (12.5) |
Reproductive issues n (%) | 0 (0.0) | 1 (20.0) | 6 (28.6) | 4 (36.4) | 17 (16.0) | 4 (16.7) | 0 (0.0) | 2 (25.0) |
Administrative issues n (%) | 0 (0.0) | 2 (40.0) | 9 (42.9) | 2 (18.2) | 13 (12.3) | 9 (37.5) | 4 (50.0) | 4 (50.0) |
JC virus n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 11 (45.8) | 0 (0.0) | 0 (0.0) |
Other n (%) | 2 (100.0) | 0 (0.0) | 1 (4.8) | 2 (18.2) | 14 (13.2) | 1 (4.2) | 0 (0.0) | 1 (12.5) |
Unknown n (%) | 0 (0.0) | 0 (0.0) | 2 (9.5) | 2 (18.2) | 27 (25.5) | 2 (8.3) | 1 (12.5) | 1 (12.5) |